Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02811159 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
A Phase 2 study, sponsored by Repros Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02811159 is a Phase 2 study that was terminated before completion, run by Repros Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT02811159, a Phase 2 study, was terminated before completion, sponsored by Repros Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
To determine the safety of extended treatment with Proellex® in women who have successfully completed either study ZPV-201 \[NCT02323646\] or ZPU-203 \[NCT02301897\] and meet eligibility criteria.
Interventions
- DRUG Telapristone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-07-26 |
| Est. Completion | 2017-05-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02811159
The ClinicalTrials.gov registry entry for NCT02811159 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telapristone acetate is the first listed.
NCT02811159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02811159 about?
NCT02811159 is a clinical study titled "An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids". To determine the safety of extended treatment with Proellex® in women who have successfully completed either study ZPV-201 \[NCT02323646\] or ZPU-203 \[NCT02301897\] and meet eligibility criteria.
What is the current status of trial NCT02811159?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2016-07-26. Estimated completion is 2017-05-04.
What interventions are being tested in trial NCT02811159?
The interventions under investigation include: Telapristone acetate (DRUG).
Who is sponsoring clinical trial NCT02811159?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.